Intec Pharma Ltd logo
Intec Pharma Ltd NTEC

Intec Pharma Ltd Net Debt 2011-2026 | NTEC

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Intec Pharma Ltd

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-13.7 M -7.95 M -39.2 M -53.3 M -16.4 M -23.6 M -5.73 M - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-5.73 M -53.3 M -22.9 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
-16.8 M - 5743.5 % $ 69.7 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
-7.39 M - 1.35 % $ 17.8 M chinaChina
AgeX Therapeutics AgeX Therapeutics
AGE
71 K - -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
2.27 M - 2.54 % $ 160 B franceFrance
AstraZeneca PLC AstraZeneca PLC
AZN
-3.91 B - - $ 96.9 B britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
-68.5 M - - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
52 M - 0.74 % $ 768 M israelIsrael
Galera Therapeutics Galera Therapeutics
GRTX
-17 M - -32.59 % $ 7.61 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
-165 M $ 3.13 - $ 651 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
-4.11 M $ 34.45 4.74 % $ 927 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
Forte Biosciences Forte Biosciences
FBRX
-58.8 M $ 20.31 1.2 % $ 263 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
-12.1 M - - $ 231 M usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
162 M $ 8.19 4.46 % $ 5.57 B spainSpain
Celyad Oncology SA Celyad Oncology SA
CYAD
-12.2 M - - $ 12.5 M belgiumBelgium
Berkeley Lights Berkeley Lights
BLI
-60.5 M - -7.31 % $ 87 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
-206 M $ 6.82 1.94 % $ 187 M israelIsrael
Generation Bio Co. Generation Bio Co.
GBIO
17.3 M - - $ 344 M usaUSA
IMV IMV
IMV
-19.8 M - - $ 13.1 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
BioNTech SE BioNTech SE
BNTX
-7.45 B $ 90.36 2.93 % $ 21.8 B germanyGermany
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-32.7 M $ 1.62 -0.61 % $ 431 M britainBritain
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-657 K - - $ 7.46 M israelIsrael
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
-3.5 M - -4.36 % $ 27 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
-87.6 M $ 2.71 -0.92 % $ 253 M israelIsrael
Anika Therapeutics Anika Therapeutics
ANIK
-31.2 M $ 15.14 2.16 % $ 217 M usaUSA
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-5.16 M - 5.93 % $ 314 M canadaCanada
Incyte Corporation Incyte Corporation
INCY
-3.06 B $ 97.08 1.55 % $ 19 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-5.46 M $ 3.39 4.17 % $ 5.58 M israelIsrael
AIkido Pharma AIkido Pharma
AIKI
-31.2 M - 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
-33.8 M - -39.0 % $ 4.57 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
-85.6 M $ 1.51 2.03 % $ 177 M usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-239 M - -0.23 % $ 916 M usaUSA
AlloVir AlloVir
ALVR
-96.6 M - 4.14 % $ 49.1 M usaUSA
Allakos Allakos
ALLK
-25 M - - $ 28.6 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
65.3 M $ 20.47 4.97 % $ 2.6 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-12 M - -11.43 % $ 502 K usaUSA